

Balloon Sinus Ostial Dilation

State(s):

☒ Idaho ☒ Montana ☒ Oregon ☒ Washington ☐ Other:

LOB(s):

☒ Commercial ☒ Medicare ☒ Medicaid

Enterprise Policy

Clinical Guidelines are written when necessary to provide guidance to providers and members in order to outline and clarify coverage criteria in accordance with the terms of the Member's policy. This Clinical Guideline only applies to PacificSource Health Plans, PacificSource Community Health Plans, and PacificSource Community Solutions in Idaho, Montana, Oregon, and Washington. Because of the changing nature of medicine, this list is subject to revision and update without notice. This document is designed for informational purposes only and is not an authorization or contract. Coverage determination are made on a case-by-case basis and subject to the terms, conditions, limitations, and exclusions of the Member's policy. Member policies differ in benefits and to the extent a conflict exists between the Clinical Guideline and the Member's policy, the Member's policy language shall control. Clinical Guidelines do not constitute medical advice nor guarantee coverage.

Background

Balloon sinus ostial dilation is a therapeutic option for selected patients with chronic rhinosinusitis (CRS) and recurrent acute rhinosinusitis (RARS) who have failed appropriate medical therapy. The procedure involves inserting a thin catheter guided by X-ray images or fluoroscopy into the nose without disrupting the surrounding bone and tissue. A small balloon is then inflated to widen blocked passageways and allow for proper drainage of sinus fluid.

Criteria

Commercial

Prior authorization is required.

PacificSource considers Balloon Sinus Ostial Dilation, with an FDA approved device, medically necessary for the treatment of medically refractory chronic sinusitis in adults when **ALL** of the following criteria have been met:

A. Either of the following:

1. Four or more documented episodes of acute bacterial rhinosinusitis within 12 continuous months; **OR**
2. Two or more of the following chronic sinusitis symptoms have been present for at least 12 continuous weeks:
 - a. Purulent drainage;
 - b. Nasal obstruction (congestion);
 - c. Facial pain-pressure-fullness; or
 - d. Decreased sense of smell.

B. Maximal medical therapy has been attempted and failed, as indicated by **ALL** of the following:

1. A minimum of 2 different antibiotic courses (at least a 7-14 day course);
2. Trial of intranasal steroids (minimum of 2 weeks);
3. Nasal saline lavage for at least 2 weeks; and
4. Treatment of underlying allergic rhinitis, if present.

C. Abnormal findings from diagnostic work-up, as indicated by **ONE or MORE** of the following:

1. Computed tomography (CT) and/or endoscopy findings document sinus pathology, including but not limited to any of the following:
 - a. Air fluid levels;
 - b. Diffuse opacification;
 - c. Mucosal thickening;
 - d. Nasal mucocele;
 - e. Ostial obstruction; **OR**
 - f. Pansinusitis.

2. Nasal endoscopy findings suggestive of significant disease; **and**

D. Balloon sinus ostial dilation is limited to the frontal, maxillary or sphenoid sinuses

Balloon Ostial Dilation is considered not medically necessary if the above criteria are not met.

Medicaid

PacificSource Community Solutions follows Guideline Note 35 of the OHP Prioritized List of Health Services for coverage of Balloon Sinus Ostial Dilation.

Medicare

PacificSource Medicare does not require prior authorization for Balloon Sinus Ostial Dilation CPT codes 31295-31298. PacificSource Medicare follows the criteria in this policy.

Experimental/Investigational/Unproven

PacificSource considers the use of Propel Bioabsorbable Steroid-Releasing Sinus Implant stent to be experimental, investigational, and unproven because the effectiveness has not been established.

Coding Information

The following list of codes are for informational purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

FESS codes

31237 Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure)

- 31253 Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including frontal sinus exploration, with removal of tissue from frontal sinus, when performed
- 31254 Nasal/sinus endoscopy, surgical with ethmoidectomy; partial (anterior)
- 31255 Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior)
- 31256 Nasal/sinus endoscopy, surgical, with maxillary antrostomy
- 31257 Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy
- 31259 Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy, with removal of tissue from sphenoid sinus
- 31267 Nasal/sinus endoscopy, surgical, with maxillary antrostomy; with removal of tissue from maxillary sinus
- 31276 Nasal/sinus endoscopy, surgical with frontal sinus exploration, with or without removal of tissue from frontal sinus
- 31287 Nasal/sinus endoscopy, surgical, with sphenoidotomy
- 31288 Nasal/sinus endoscopy, surgical, with sphenoidotomy; with removal of tissue from the sphenoid sinus

Balloon Ostial Dilation codes

- 31295 Nasal/sinus endoscopy, Surgical: with Dilation of maxillary sinus ostium (e.g. balloon dilation), transnasal or Via Canine Fossa
- 31296 Nasal/sinus endoscopy, Surgical: with Dilation of Frontal Sinus Ostium (e.g. Balloon Dilation)
- 31297 Nasal/sinus endoscopy, Surgical: with Dilation of Sphenoid sinus ostium (e.g. Balloon dilation)
- 31298 Nasal/sinus endoscopy, surgical; with dilation of frontal and sphenoid sinus ostia (e.g. balloon dilation)

CPT® codes, descriptions and materials are copyrighted by the American Medical Association (AMA).

HCPCS® codes, descriptions and materials are copyrighted by Centers for Medicare and Medicaid Services (CMS).

Related Policies

Anesthesia Care with Endoscopy

Bilateral or Multiple Procedure Guidelines

References

Acclarent®. Balloon Sinuplast Systems. 2016.

<https://www.acclarent.com/solutions/products/balloon-sinuplasty-system>

American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Clinical consensus statement: Balloon dilation of the sinuses. Feb 1, 2018. Accessed 3/26/2019, 1/27/2020, 8/12/2020, 12/22/2020

<https://www.entnet.org/content/new-clinical-consensus-statement-balloon-dilation-sinuses>

American Academy of Otolaryngology- Head and Neck Surgery Clinical Practice Guidelines, (Update): Adult Sinusitis. Apr, 2015. Accessed 3/26/2019, 1/27/2020, 8/12/2020, 12/22/2020

<http://www.entnet.org/content/clinical-practice-guidelines>

American Academy of Otolaryngology- Head and Neck Surgery (AAO-HNS) Policy Statement: Dilation of sinuses, any method (e.g., balloon, etc.) Revised Mar 12, 2017. Accessed 3/26/2019, 1/27/2020, 8/12/2020, 12/22/2020

<http://www.entnet.org/content/position-statements>

Bikhazi N et al, REMODEL Study Investigators. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial with 1-year follow-up. Am J Rhinol Allergy. 2014 Jul-Aug;28(4):323-9. Accessed 3/26/2019, 1/27/2020, 8/12/2020, 12/22/2020

<https://www.ncbi.nlm.nih.gov/pubmed/24823902>

Bizaki AJ et al, A Controlled, Randomized Clinical Study on the Impact of Treatment on Antral Mucociliary Clearance: Uncinectomy Versus Balloon Sinuplasty. Ann Otol Rhinol Laryngol 2016, May;125(5): 408-14. Accessed 3/26/2019, 1/27/2020, 8/12/2020, 12/22/2020

<http://www.ncbi.nlm.nih.gov/pubmed/26611244>

Chandra RK, Kern RC, Cutler JL, Welch KC, Russell PT. REMODEL larger cohort with long-term outcomes and meta-analysis of standalone balloon dilation studies. Laryngoscope. 2016 Jan;126(1):44-50. Accessed 3/26/2019, 1/27/2020, 8/12/2020, 12/22/2020

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132108/>

Hayes Health Technology Assessment. Balloon Sinuplasty for Treatment of Chronic rhinosinusitis in Adult Patients. (2019, September 19. Annual review 2021, January 4). Hayes, A division of TractManager

Hayes Medical Technology Directory. Balloon Sinuplasty for Treatment of Chronic Sinusitis in Pediatric Patients. (2019, September 19. Annual review 2021, January 4). Hayes, A division of TractManager.

Medtronic. NuVent EM Balloon Sinus Dilation System. 2018.

<http://www.medtronic.com/us-en/healthcare-professionals/products/ear-nose-throat/balloonsinus-dilation/nuvent-em-balloon-sinus-dilation-system.html>

Payne SC et al. Medical therapy versus sinus surgery by using balloon sinus dilation technology: A prospective multicenter study. Am J Rhinol Allergy. 2016 Jul; 0 (4):279-86. Accessed 3/26/2019, 1/27/2020, 8/12/2020, 12/22/2020

<https://www.ncbi.nlm.nih.gov/pubmed/27325205>

U.S. Food and Drug Administration (FDA). 510(k) premarket notification database.

Available at URL address: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>

U.S. Food and Drug Administration (FDA). Premarket approval database.

Available at URL address: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>

Appendix

Policy Number: [Policy Number]

Effective: 1/1/2021

Next review: 1/1/2022

Policy type: Enterprise

Author(s): [Authors]

Depts: Health Services

Applicable regulation(s): N/A

Commercial Ops: 10/2021

Government Ops: 10/2021